Clinical Trials · NCT07087795
A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 Diabetes
- Phase
- Phase 1
- Recruitment status
- Active Not Recruiting
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 96
- Start date
- Jul 2025
- Locations
- 1 site, Germany
- Primary endpoint
- Part A: Change in time in range (TIR) 3.9-10.0 mmol/L (70-80 mg/dL)